Jens Eckstein has been named President of SR One, GSK’s independent healthcare venture organisation, effective 1 October. Jens will report to R&D Chairman Moncef Slaoui and be based in Boston. He replaces Christoph Westphal, who will be leaving GSK at the end of the year to focus on external business interests, including the Longwood Founder’s Fund, in which GSK is an investor. As President of SR One, Jens will oversee the overall activities of the group and manage the investment and support team. He will be responsible for evaluating the technology, business model, management team, investor base and financial status of non-public companies in promising technologies and sciences in order to determine their suitability for investment by SR One.
